New treatments for prostate cancer using small molecule inhibitors
Small Molecule ERG Inhibitors for Prostate Cancer
This study is looking at new treatments for prostate cancer by targeting a specific protein called ERG, which can make the cancer harder to treat, especially when it becomes resistant to standard therapies; if you're a patient, you might have the chance to try out these new treatments in a trial to see how well they work and if they're safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10999567 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule inhibitors that target the ERG transcription factor, which is involved in the progression of prostate cancer. The study aims to address the challenge of treatment resistance in prostate cancer, particularly in cases that have progressed to castration-resistant prostate cancer (CRPC). By exploring the role of ERG and its interactions with the androgen receptor, the research seeks to create more effective therapies that can improve patient outcomes. Patients may be involved in trials that test these new inhibitors to assess their effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, especially those with castration-resistant prostate cancer.
Not a fit: Patients with early-stage prostate cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, particularly for patients who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown promise in targeting transcription factors for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Bushweller, John Hackett — University of Virginia
- Study coordinator: Bushweller, John Hackett
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.